Molecular mechanisms in therapy of acid-related diseases
about
Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleedingPhysiological implications of biased signaling at histamine H2 receptors.Protective effect of N-acetylcysteine against ethanol-induced gastric ulcer: A pharmacological assessment in mice.Acid peptic diseases: pharmacological approach to treatment.Gastric H+,K+-ATPase.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionPharmacokinetics and Pharmacodynamics of Azeloprazole Sodium, a Novel Proton Pump Inhibitor, in Healthy Japanese Volunteers.Gastrin-releasing peptide receptor antagonist or N-acetylcysteine combined with omeprazol protect against mitochondrial complex II inhibition in a rat model of gastritis.Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.Crystal structure and bonding analysis of the first dinuclear calcium(II)-proton-pump inhibitor (PPI) `butterfly molecule': a combined microcrystal synchrotron and DFT study.Intravenous ilaprazole is more potent than oral ilaprazole against gastric lesions in rats
P2860
Q27025841-882E0599-1EF9-4B13-9A2F-1799EDF0F10CQ35161152-FDAB26C5-4C41-4A32-959B-89758839459EQ36051038-76773898-2A3A-469C-AD52-525A3AD66FE4Q37913063-38E5B518-7654-4EF6-B52A-A5B13B648ABFQ38111736-65D4F39F-91AF-46BF-842E-F238A9619B06Q38415822-6FF222F6-E686-4C7E-A51F-B41D9B6B30E6Q38900694-CDEAD814-C4F4-4712-9E66-D5BE45053435Q39746768-8369E4B2-9D18-4175-9666-FF5F1A242055Q42023861-3D270979-3F4A-4D4E-8AE5-C6FB2945DCC4Q42371575-C0BBDCCB-4AB9-44DB-93EF-944E8CAD4B23Q49381732-C1EA1517-80C1-4843-BD35-1977173D3B8AQ51385008-12AD8BA6-B289-42B7-A94B-252929C02EC1Q52881408-03534798-4CA3-4AE3-81D0-7EFC66A9B7CDQ53160898-5E78B785-E7AA-4BB0-8EB9-1DC69BD1714EQ57222290-4D21A1C1-B751-411C-B2F0-B63BF09FCE10
P2860
Molecular mechanisms in therapy of acid-related diseases
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Molecular mechanisms in therapy of acid-related diseases
@ast
Molecular mechanisms in therapy of acid-related diseases
@en
Molecular mechanisms in therapy of acid-related diseases
@nl
type
label
Molecular mechanisms in therapy of acid-related diseases
@ast
Molecular mechanisms in therapy of acid-related diseases
@en
Molecular mechanisms in therapy of acid-related diseases
@nl
prefLabel
Molecular mechanisms in therapy of acid-related diseases
@ast
Molecular mechanisms in therapy of acid-related diseases
@en
Molecular mechanisms in therapy of acid-related diseases
@nl
P2093
P2860
P3181
P1476
Molecular mechanisms in therapy of acid-related diseases
@en
P2093
P2860
P2888
P304
P3181
P356
10.1007/S00018-007-7249-X
P407
P577
2008-01-01T00:00:00Z